LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study

Zacks11-20

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484041659?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","is_english":true,"pubTime":"2024-11-20 04:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2484041659","market":"us","top_or_hot":-1,"title":"LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study","media":"Zacks","content":"<div>\n<p>Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-...</p>\n\n<a href=\"https://finance.yahoo.com/news/lly-oral-cholesterol-drug-lowers-200000359.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 04:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lly-oral-cholesterol-drug-lowers-200000359.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-...</p>\n\n<a href=\"https://finance.yahoo.com/news/lly-oral-cholesterol-drug-lowers-200000359.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1988902786.USD","symbol_name":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/lly-oral-cholesterol-drug-lowers-200000359.html","article_id":"2484041659","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484041659","pubTimestamp":1732046400,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplinreduced lipoprotein or Lp levels in adults with high risk of cardiovascular events in a 12-week phase II study.In the study, muvalaplin led to a significant reduction in elevated Lp levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp from baseline to week 12. Using an intact Lp assay, the reductions in Lp levels were 47.6% for the 10 mg dose, 81.7% for the 60 mg dose and 85.8% for the 240 mg dose. With an apo assay, the reductions were 40.4% , 70.0%  and 68.9% . Muvalaplin also met secondary endpointsfor all three doses. Treatment-related adverse events occurred in 14.9% of the placebo group, 5.9% of the 10 mg group, 14.3% of the 60 mg group and 14.7% of the 240 mg group.Lilly’s stock has risen 24.7% so far this year compared with an increase of 3.4% for the industry.Eli Lilly and Company  : Free Stock Analysis Report","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","AMGN":"安进","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","BK4532":"文艺复兴科技持仓","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","BK4534":"瑞士信贷持仓","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4581":"高盛持仓","LLY":"礼来","LU2063271972.USD":"富兰克林创新领域基金","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","NVS":"诺华","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IONS":"Ionis Pharmaceuticals, Inc","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","BK4007":"制药","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","BK4139":"生物科技","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD"},"translate_title":"LLY口服降胆固醇药物在II期研究中降低脂蛋白水平","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"NVS":1,"IONS":1,"LLY":1},"content_text":"Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) or Lp(a) levels in adults with high risk of cardiovascular events in a 12-week phase II study.\nIn the study, muvalaplin led to a significant reduction in elevated Lp(a) levels compared to placebo, meeting the study’s primary endpoint of percent change in Lp(a) from baseline to week 12.  Using an intact Lp(a) assay, the reductions in Lp(a) levels were 47.6% for the 10 mg dose, 81.7% for the 60 mg dose and 85.8% for the 240 mg dose. With an apo(a) assay, the reductions were 40.4% (10 mg), 70.0% (60 mg) and 68.9% (240 mg). Muvalaplin also met secondary endpoints for all three doses. Treatment-related adverse events occurred in 14.9% of the placebo group, 5.9% of the 10 mg group, 14.3% of the 60 mg group and 14.7% of the 240 mg group.\nLilly’s stock has risen 24.7% so far this year compared with an increase of 3.4% for the industry.\nImage Source: Zacks Investment Research\nHow Does LLY’s Muvalaplin Work?\nElevated Lp(a) levels are strongly associated with coronary disease. High levels of lipoprotein in your blood can block arteries by sticking up to their walls, leading to heart disease and stroke. However, currently available cholesterol-lowering medicines are not approved to lower Lp(a) levels in people living with cardiovascular disease. This creates a significant unmet need for once-daily pills like muvalaplin, which has shown the potential to reduce the risk of heart attacks or strokes. Muvalaplin has a novel mechanism of action. It disrupts the interaction between apolipoprotein(a) and apolipoprotein(b, which prevents the formation of Lp(a). Apolipoprotein(a) is a key component of Lp(a), which increases the risk of cardiovascular events. \nOther Companies Making Lp(a)-Lowering Drugs\nSome injectable treatments for lowering Lp(a) are in phase III studies including Lilly’s own RNA-based candidate, lepodisiran. Other RNA based phase III injectable candidates being developed to lower levels of Lp(a) are Novartis’ NVS pelacarsen, which it is developing in partnership with Ionis Pharmaceuticals IONS and Amgen’s AMGN olpasiran. NVS and IONS plan to release data from the phase III study on pelacarsen next year. Data from a phase II study on Amgen’s olpasiran showed that the candidate reduced Lp(a)levels by more than 95% in patients with established atherosclerotic cardiovascular disease.\nLLY’s Zacks Rank\nEli Lilly has a Zacks Rank #3 (Hold) currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\n\nEli Lilly and Company Price and Consensus\n\nEli Lilly and Company price-consensus-chart | Eli Lilly and Company Quote\n\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovartis AG (NVS) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nAmgen Inc. (AMGN) : Free Stock Analysis Report\nIonis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484041659"}